Back to Search
Start Over
Ganciclovir concentrations in the cerebral extracellular space after valganciclovir treatment; a case study.
- Source :
-
BMJ case reports [BMJ Case Rep] 2015 Dec 15; Vol. 2015. Date of Electronic Publication: 2015 Dec 15. - Publication Year :
- 2015
-
Abstract
- Nearly all glioblastomas (GBMs), brain tumours with very poor prognosis, are infected with human cytomegalovirus (CMV). The anti-CMV drug valganciclovir (VGCV) has shown promise as a treatment option for patients with GBM, but its penetration into the central nervous system (CNS) is unknown. Here we describe a patient with GMB receiving VGCV in whom an intracerebral microdialysis catheter was implanted and ganciclovir (GCV) concentrations in brain extracellular fluid (BECF) and serum were monitored. GCV was rapidly absorbed. Cmax values (at 3 h) in serum and BECF were 19.6 and 10.2 µmol/L, T½ values were 3.2 and 4.5 h, and plasma and BECF AUC0-∞ values were 90.7 and 75.9 µmol h/L, respectively. Thus, VGCV treatment results in significant intracerebral levels of GCV that may be sufficient for therapeutic effects. Further studies of this drug in patients with GBM are warranted.<br /> (2015 BMJ Publishing Group Ltd.)
- Subjects :
- Antiviral Agents administration & dosage
Brain metabolism
Brain Neoplasms virology
Cytomegalovirus isolation & purification
Cytomegalovirus Infections drug therapy
Cytomegalovirus Infections metabolism
Drug Monitoring
Extracellular Space metabolism
Follow-Up Studies
Ganciclovir administration & dosage
Glioblastoma virology
Humans
Male
Microdialysis
Middle Aged
Treatment Outcome
Valganciclovir
Antiviral Agents pharmacokinetics
Brain Neoplasms metabolism
Ganciclovir analogs & derivatives
Ganciclovir pharmacokinetics
Glioblastoma metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1757-790X
- Volume :
- 2015
- Database :
- MEDLINE
- Journal :
- BMJ case reports
- Publication Type :
- Academic Journal
- Accession number :
- 26670887
- Full Text :
- https://doi.org/10.1136/bcr-2014-207694